Cannabis as a Source of Approved Drugs: A New Look at an Old Problem

被引:11
作者
Gabarin, Adi [1 ]
Yarmolinsky, Ludmila [1 ]
Budovsky, Arie [2 ]
Khalfin, Boris [1 ]
Ben-Shabat, Shimon [1 ]
机构
[1] Ben Gurion Univ Negev, Fac Hlth Sci, Dept Clin Biochem & Pharmacol, IL-84105 Beer Sheva, Israel
[2] Barzilai Univ, Res & Dev Author, Med Ctr, IL-7830604 Ashqelon, Israel
来源
MOLECULES | 2023年 / 28卷 / 23期
关键词
cannabis; drugs; cannabidiol; tetrahydrocannabinol; HIGH-POTENCY CANNABIS; ENDOCANNABINOID SYSTEM; SYNTHETIC CANNABINOIDS; MARIJUANA; HEALTH; PHARMACOLOGY; DEMENTIA; SYNERGY; DISEASE; BRAIN;
D O I
10.3390/molecules28237686
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cannabis plants have been used in medicine since ancient times. They are well known for their anti-diabetic, anti-inflammatory, neuroprotective, anti-cancer, anti-oxidative, anti-microbial, anti-viral, and anti-fungal activities. A growing body of evidence indicates that targeting the endocannabinoid system and various other receptors with cannabinoid compounds holds great promise for addressing multiple medical conditions. There are two distinct avenues in the development of cannabinoid-based drugs. The first involves creating treatments directly based on the components of the cannabis plant. The second involves a singular molecule strategy, in which specific phytocannabinoids or newly discovered cannabinoids with therapeutic promise are pinpointed and synthesized for future pharmaceutical development and validation. Although the therapeutic potential of cannabis is enormous, few cannabis-related approved drugs exist, and this avenue warrants further investigation. With this in mind, we review here the medicinal properties of cannabis, its phytochemicals, approved drugs of natural and synthetic origin, pitfalls on the way to the widespread clinical use of cannabis, and additional applications of cannabis-related products.
引用
收藏
页数:21
相关论文
共 213 条
  • [1] Validation of a combined Fast blue BB and 4-Aminophenol colorimetric test for indication of Hemp-type and Marijuana-type cannabis
    Acosta, Alexander
    Li, Li
    Weaver, Mike
    Capote, Ryan
    Perr, Jeannette
    Almirall, Jose
    [J]. FORENSIC CHEMISTRY, 2022, 31
  • [2] Targeting the endocannabinoid system: future therapeutic strategies
    Aizpurua-Olaizola, Oier
    Elezgarai, Izaskun
    Rico-Barrio, Irantzu
    Zarandona, Iratxe
    Etxebarria, Nestor
    Usobiaga, Aresatz
    [J]. DRUG DISCOVERY TODAY, 2017, 22 (01) : 105 - 110
  • [3] Ali A, 2015, PAK J PHARM SCI, V28, P1389
  • [4] Marijuana Use Patterns Among Patients with Inflammatory Bowel Disease
    Allegretti, Jessica Ravikoff
    Courtwright, Andrew
    Lucci, Matthew
    Korzenik, Joshua R.
    Levine, Jonathan
    [J]. INFLAMMATORY BOWEL DISEASES, 2013, 19 (13) : 2809 - 2814
  • [5] Synthetic cannabinoids in the kidneys
    Alp, Alper
    Akdam, Hakan
    Avcioglu, Banu Yilmaz
    Ersan, Sibel
    [J]. REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2017, 63 (01): : 10 - 12
  • [6] Alsherbiny Muhammad A, 2018, Medicines (Basel), V6, DOI 10.3390/medicines6010003
  • [7] Aluko RE, 2017, SUSTAINABLE PROTEIN SOURCES, P121, DOI 10.1016/B978-0-12-802778-3.00007-X
  • [8] Cannabis and Canabidinoids on the Inflammatory Bowel Diseases: Going Beyond Misuse
    Alves de Carvalho, Antonelly Cassio
    de Souza, Gabriela Achete
    de Marqui, Samylla Vaz
    Guiguer, Elen Landgraf
    Araujo, Adriano Cressoni
    Rubira, Claudio Jose
    Goulart, Ricardo de Alvares
    Prync Flato, Uri Adrian
    dos Santos Bueno, Patricia Cincotto
    Buchaim, Rogerio Leone
    Barbalho, Sandra M.
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (08)
  • [9] The synthetic cannabinoids phenomenon: from structure to toxicological properties. A review
    Alves, Vera L.
    Goncalves, Joao L.
    Aguiar, Joselin
    Teixeira, Helena M.
    Camara, Jose S.
    [J]. CRITICAL REVIEWS IN TOXICOLOGY, 2020, 50 (05) : 359 - 382
  • [10] Amtmann Dagmar, 2004, Am J Hosp Palliat Care, V21, P95, DOI 10.1177/104990910402100206